Business
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceu...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Holds Annual Meeting of Shareholders and Announces Election of DirectorsToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 12, 2025 as directors through the next annual meeting. Shareholders also voted in favor of the appointment of PricewaterhouseCoopers LLP as the company's auditors.Detailed voting results for the election of directors are set out in the table below.NameForAgainstKen d'Entremont95.091% (11,232,130)4.909% (579,891)Harmony Garges94.719% (11,188,190)5.281% (623,831)Benoit Gravel92.187% (10,889,190)7.813% (922,831)Michael Mueller94.719% (11,188,190)5.281% (623,831)Stephen Nelson96.452% (11,392,966)3.548% (419,055)Nancy Phelan94.719% (11,188,190)5.281% (623,831)Menassie Taddese94.714% (11,187,690)5.286% (624,331) Shareholders also cast 14,240,037 (99.508%) votes for and withheld 70,444 (0.492%) votes from the appointment of PricewaterhouseCoopers LLP as the company's auditors. All proposals were therefore approved.A report of the voting results on all matters voted on at the annual meeting will be filed with Canadian securities regulatory authorities at www.sedarplus.ca.About MedexusMedexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and allergy, dermatology, and rheumatology. For more information about Medexus and its product portfolio, please see the company's corporate website at www.medexus.com and its filings on SEDAR+ at www.sedarplus.ca.ContactsKen d'Entremont | CEO, Medexus PharmaceuticalsTel: 905-676-0003 | Email: [email protected] Buschman | CFO, Medexus PharmaceuticalsTel: 416-577-6216 | Email: [email protected] Rutherford | Adelaide CapitalTel: 480-625-5772 | Email: [email protected] statementsCertain statements made in this news release contain forward-looking information within the meaning of applicable securities laws, also known and/or referred to as \"forward-looking information\" or \"f...